Evidence map›Paper›PMID 38680668›Full record

ArticleRespirology case reports2024

Recommencement of atezolizumab with associated pulmonary sarcoid-like reaction.

Khai Tam, Michael Wallace, Siobhain Mulrennan

Abstract readCase Reports
In one paragraph

Article in Respirology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Khai TamRespiratory and Hepatology Department Sir Charles Gairdner Hospital Perth Western Australia Australia.ORCID https://orcid.org/0009-0005-3552-9064
Michael WallaceRespiratory and Hepatology Department Sir Charles Gairdner Hospital Perth Western Australia Australia.
Siobhain MulrennanRespiratory and Hepatology Department Sir Charles Gairdner Hospital Perth Western Australia Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 81 year old male with Child-Pugh A cirrhosis and metastatic hepatocellular carcinoma (HCC) treated with 3-weekly atezolizumab and bevacizumab developed a pulmonary sarcoid-like reaction (SLR) after 5 months. Atezolizumab, an immune checkpoint inhibitor, was identified as the likely culprit. He was treated with prednisolone, resulting in improvement, and was successfully rechallenged with both atezolizumab and bevacizumab.

Indexed as

atezolizumabimmune checkpoint inhibitorrecommencementsarcoid‐like reactionsarcoidosis

Identifiers

PMID38680668
PMCPMC11052663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.